medigraphic.com
ISSN 1561-3011 (Electronic)

2022, Number 1

<< Back Next >>

Rev Cubana Invest Bioméd 2022; 41 (1)

Effect of Surfacensup>®, pulmonary surfactant, on the antimicrobial activity of cefotaxime and amikacin

Lugones LGY, Pérez CR, Morilla GA, Espinosa CI, Blanco HO

Language: Spanish
References: 36
Page: 1-22
PDF size: 315.79 Kb.


ABSTRACT

Introduction: The efficacy of antibiotics in respiratory diseases is debated, because it fails to reach the infected lung area. Pulmonary surfactant is considered a drug transporter due to its biophysical properties.
Objective: To evaluate the effect of Surfacen on the activity of cefotaxime and amikacin against strains associated with in vitro respiratory diseases.
Methods: The antibacterial activity of cefotaxime and amikacin alone or combined with Surfacen® was evaluated in vitro using the lethality curve over time of Staphylococcus aureus, Escherichia coli and Pseudomona aeruginosa, by the method of quantitative suspension by dilution and counting. Standard definitions of synergy, antagonism or indifference were used to assess the effect of Surfacen® on antibiotic activity.
Results: Surfacen does® not affect the antibacterial activity of cefotaxime or increases it by obtaining a synergism at the concentration of 16 μg/mL for Staphylococcus aureus and at concentrations of 8 and 16 μg/mL for Pseudomona aeruginosa. In the case of amikacin, although it showed indifference, antagonism was also observed, which is characteristic of aminoglycosides in the presence of pulmonary surfactant.
Conclusions: The effect of Surfacen on antibiotic activity was investigated. When cefotaxime is combined with Surfacen its activity is not affected, however, the activity of amikacin was affected, showing a dual behavior dependent on concentration. This study will contribute in the future to the use of Surfacen as a vehicle for the supply of antibiotics to the lung.


REFERENCES

  1. Newman SP. Drug delivery to the lungs: challenges and opportunities. Therapeutic delivery. 2017 Jul;8(8):647-661. eng. Epub 2017/07/22. DOI: https://10.4155/tde-2017-0037

  2. Baer B, Souza LMP, Pimentel AS, Veldhuizen RAW. New insights into exogenous surfactant as a carrier of pulmonary therapeutics. Biochemical pharmacology. 2019 Jun;164:64-73. eng. Epub 2019/04/01. DOI: https://10.1016/j.bcp.2019.03.036

  3. Blanco O, Pérez Gil J. Biochemical and pharmacological differences between preparations of exogenous natural surfactant used to treat Respiratory Distress Syndrome: role of the different components in an efficient pulmonary surfactant. European journal of pharmacology. 2007 Jul 30;568(1-3):1-15. eng. Epub 2007/06/05. DOI: https://10.1016/j.ejphar.2007.04.035

  4. Hidalgo A, Cruz A, Pérez Gil J. Barrier or carrier? Pulmonary surfactant and drug delivery. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik eV. 2015 Sep;95(Pt A):117-27. eng. Epub 2015/02/25. DOI: https://10.1016/j.ejpb.2015.02.014

  5. Quon BS, Goss CH, Ramsey BW. Inhaled antibiotics for lower airway infections. Annals of the American Thoracic Society. 2014 Mar;11(3):425-34. eng. Epub 2014/03/29. DOI: https://10.1513/AnnalsATS.201311-395FR

  6. Shetty N, Park H, Zemlyanov D, Mangal S, Bhujbal S, Zhou QT. Influence of excipients on physical and aerosolization stability of spray dried high-dose powder formulations for inhalation. International journal of pharmaceutics. 2018 Jun 10;544(1):222-234. eng. Epub 2018/04/22. DOI: https://10.1016/j.ijpharm.2018.04.034

  7. Khatib I, Khanal D, Ruan J, Cipolla D, Dayton F, Blanchard JD, Chan HK. Ciprofloxacin nanocrystals liposomal powders for controlled drug release via inhalation. International journal of pharmaceutics. 2019 Jul 20;566:641-651. eng. Epub 2019/06/17. DOI: https://10.1016/j.ijpharm.2019.05.068

  8. Ari A, Fink JB, Dhand R. Inhalation therapy in patients receiving mechanical ventilation: an update. Journal of aerosol medicine and pulmonary drug delivery. 2012 Dec;25(6):319-32. eng. Epub 2012/08/04. DOI: https://10.1089/jamp.2011.0936

  9. Niederman MS. Adjunctive Nebulized Antibiotics: What Is Their Place in ICU Infections? [Review]. Frontiers in Medicine. 2019 2019-May-08;6(99). English. DOI: https://10.3389/fmed.2019.00099

  10. Bassetti M, Vena A, Russo A, Peghin M. Inhaled Liposomal Antimicrobial Delivery in Lung Infections. Drugs. 2020 Sep;80(13):1309-1318. eng. Epub 2020/07/22. DOI: https://10.1007/s40265-020-01359-z

  11. Stichtenoth G, Haegerstrand-Björkman M, Walter G, Linderholm B, Herting E, Curstedt T. Comparison of Polymyxin E and Polymyxin B as an Additive to Pulmonary Surfactant in Escherichia coli Pneumonia of Ventilated Neonatal Rabbits. Biomedicine hub. 2017 May-Aug;2(2):1-9. eng. Epub 2017/06/24. DOI: https://10.1159/000475877

  12. Baer B, Veldhuizen EJA, Possmayer F, Yamashita C, Veldhuizen R. The wet bridge transfer system: a novel tool to assess exogenous surfactant as a vehicle for intrapulmonary drug delivery. Discovery medicine. 2018 Nov;26(144):207-218. eng. Epub 2019/01/30. Cited in: Pubmed; PMID 30695680.

  13. Basabe Burgos O, Zebialowicz J, Stichtenoth G, Curstedt T, Bergman P, Johansson J, Rising A. Natural Derived Surfactant Preparation As a Carrier of Polymyxin E for Treatment of Pseudomonas aeruginosa Pneumonia in a Near-Term Rabbit Model. Journal of aerosol medicine and pulmonary drug delivery. 2019 Apr;32(2):110-118. eng. Epub 2018/10/20. DOI: https://10.1089/jamp.2018.1468

  14. van 't Veen A, Mouton JW, Gommers D, Kluytmans JA, Dekkers P, Lachmann B. Influence of pulmonary surfactant on in vitro bactericidal activities of amoxicillin, ceftazidime, and tobramycin. Antimicrobial agents and chemotherapy. 1995 Feb;39(2):329-33. eng. Epub 1995/02/01. DOI: https://10.1128/aac.39.2.329

  15. Gotfried MH, Shaw JP, Benton BM, Krause KM, Goldberg MR, Kitt MM, Barriere SL. Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics. Antimicrobial agents and chemotherapy. 2008 Jan;52(1):92-7. eng. Epub 2007/10/10. DOI: https://10.1128/aac.00875-07

  16. Morilla Guzmán AA, Díaz Casañas E, Ávila Albuerne Y, Barrese Pérez Y, Fernández Limia O, Uranga Piña R. Seguridad del tratamiento con Surfacen® en recién nacidos pretérminos con síndrome de dificultad respiratoria. Revista Cubana de Pediatría. 2019 2019-03-18;91(2:e700):1-14. Epub 2019-03-29. Disponible en: http://www.revpediatria.sld.cu/index.php/ped/article/view/700

  17. Rodriguez Moya VS, Gallo Borrero CM, Santos Areas D, Prince Martinez IA, Diaz Casanas E, Lopez Herce Cid J. Exogenous surfactant and alveolar recruitment in the treatment of the acute respiratory distress syndrome. The clinical respiratory journal. 2017 Nov;11(6):1032-1039. eng. Epub 2016/02/18. DOI: https://10.1111/crj.12462

  18. Barrese Pérez Y, Hidalgo Sánchez AO, Ávila Albuerne Y, Uranga Piña R, Díaz Casañas E, Fernández Limia O. Surfactante pulmonar exógeno en adultos con síndrome de dificultad respiratoria aguda. Neumología y cirugía de tórax.2015;74:172-178. Disponible en: http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S0028-37462015000300002&nrm=iso

  19. Blanco O, Cruz A, Ospina OL, López Rodriguez E, Vázquez L, Pérez Gil J. Interfacial behavior and structural properties of a clinical lung surfactant from porcine source. Biochimica et biophysica acta. 2012 Nov;1818(11):2756-66. eng. Epub 2012/07/10. DOI: https://10.1016/j.bbamem.2012.06.023

  20. Monté Cerero L, Martínez Casanueva R. Microorganismos aislados en pacientes ingresados. Hospital "Salvador Allende", La Habana. Febrero a junio de 2015. 2017. 2017 2017-06-28;16(4):12. Epub 2017-09-14. Disponible en http://www.revhabanera.sld.cu/index.php/rhab/article/view/1326

  21. Torres A, Motos A, Battaglini D, Li Bassi G. Inhaled amikacin for severe Gram-negative pulmonary infections in the intensive care unit: current status and future prospects. Critical care (London, England). 2018 Dec 17;22(1):343. eng. Epub 2018/12/19. DOI: https://10.1186/s13054-018-1958-4

  22. Logre E, Enser M, Tanaka S, Dubert M, Claudinon A, Grall N, Mentec H, Montravers P, Pajot O. Amikacin pharmacokinetic/pharmacodynamic in intensive care unit: a prospective database. Annals of intensive care. 2020 2020/06/08;10(1):75. DOI: https://10.1186/s13613-020-00685-5

  23. Oliva A, Carmona Y, de La C. López E, Álvarez R, Aung MS, Kobayashi N, Quiñones D. Characterization of Neonatal Infections by Gram-Negative Bacilli and Associated Risk Factors, Havana, Cuba. Infectious Disease Reports. 2021;13(1):219-229. Cited in: Pubmed; PMID DOI: https://10.3390/idr13010025

  24. White RL, Burgess DS, Manduru M, Bosso JA. Comparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E test. Antimicrobial agents and chemotherapy. 1996 Aug;40(8):1914-8. eng. Epub 1996/08/01. DOI: https://10.1128/aac.40.8.1914

  25. Manzanares D, Díaz E, Alfonso W, Escobar A, Colomé H, Muñoz M, Noa M, Rabell S, Hidalgo O. Surfactante pulmonar natural porcino. República de Cuba, Patente A. 1995;A 61:35-42K.

  26. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing. 28th ed. CLSI supplement M100S. Wayne, PA: Clinical and Laboratory Standards Institute; 2018.

  27. Johnson PA. Novel understandings of host cell mechanisms involved in chronic lung infection: Pseudomonas aeruginosa in the cystic fibrotic lung. Journal of infection and public health. 2019 Mar-Apr;12(2):242-246. eng. Epub 2018/11/22. DOI: https://10.1016/j.jiph.2018.10.014

  28. Ho DK, Nichols BLB, Edgar KJ, Murgia X, Loretz B, Lehr CM. Challenges and strategies in drug delivery systems for treatment of pulmonary infections. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik eV. 2019 Nov;144:110-124. eng. Epub 2019/09/08. DOI: https://10.1016/j.ejpb.2019.09.002

  29. Schwameis R, Erdogan Yildirim Z, Manafi M, Zeitlinger MA, Strommer S, Sauermann R. Effect of pulmonary surfactant on antimicrobial activity in vitro. Antimicrobial agents and chemotherapy. 2013 Oct;57(10):5151-4. eng. Epub 2013/07/24. DOI: https://10.1128/aac.00778-13

  30. Birkun A. Exogenous pulmonary surfactant as a vehicle for antimicrobials: assessment of surfactant-antibacterial interactions in vitro. Scientifica. 2014;2014:930318. eng. Epub 2014/05/31. DOI: https://10.1155/2014/930318

  31. Stichtenoth G, Linderholm B, Björkman MH, Walter G, Curstedt T, Herting E. Prophylactic intratracheal polymyxin B/surfactant prevents bacterial growth in neonatal Escherichia coli pneumonia of rabbits. Pediatric research. 2010 Apr;67(4):369-74. eng. Epub 2009/12/26. DOI: https://10.1203/PDR.0b013e3181d026f6

  32. Birkun AA, Kubyshkin AV, Novikov NY, Krivorutchenko YL, Fedosov MI, Postnikova ON, Snitser AA. Joint Intratracheal Surfactant-Antibacterial Therapy in Experimental Pseudomonas-Induced Pneumonia. Journal of aerosol medicine and pulmonary drug delivery. 2015 Aug;28(4):299-307. eng. Epub 2014/12/18. DOI: https://10.1089/jamp.2014.1161

  33. Clancy JP, Dupont L, Konstan MW, Billings J, Fustik S, Goss CH, Lymp J, Minic P, Quittner AL, Rubenstein RC, Young KR, Saiman L, Burns JL, Govan JR, Ramsey B, Gupta R. Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection. Thorax. 2013 Sep;68(9):818-25. eng. Epub 2013/06/12. DOI: https://10.1136/thoraxjnl-2012-202230

  34. Griffith DE, Eagle G, Thomson R. Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT). A Prospective, Open-Label, Randomized Study. 2018 Dec 15;198(12):1559-1569. DOI: https://10.1164/rccm.201807-1318OC

  35. Haworth CS, Bilton D, Chalmers JD, Davis AM, Froehlich J, Gonda I, Thompson B, Wanner A, O'Donnell AE. Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials. The Lancet Respiratory medicine. 2019 Mar;7(3):213-226. eng. Epub 2019/01/20. DOI: https://10.1016/s2213-2600(18)30427-2

  36. Marier JF, Brazier JL, Lavigne J, Ducharme MP. Liposomal tobramycin against pulmonary infections of Pseudomonas aeruginosa: a pharmacokinetic and efficacy study following single and multiple intratracheal administrations in rats. The Journal of antimicrobial chemotherapy. 2003 Aug;52(2):247-52. eng. Epub 2003/07/03. DOI: https://10.1093/jac/dkg317




2020     |     www.medigraphic.com